EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study

Hanne Blakstad iD, Eduardo Erasmo Mendoza Mireles, Liv Cathrine Heggebø, Henriette Magelssen, Mette Sprauten, Tom Børge Johannesen, Einar Osland Vik-Mo, Henning Leske iD, Pitt Niehusmann, Karoline Skogen, Eirik Helseth iD, Kyrre Eeg Emblem und 1 weitere

Neuro-Oncology Practice · 12.01.2024 · 11 (1) · 36-45

DOI: 10.1093/nop/npad063 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Neuro-Oncology Practice, online erschienen am 03.10.2023. Verfasst von Hanne Blakstad und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Oslo University Hospital, Oslo, Norway. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union’s Horizon 2020 Programmes, European Research Council, Norwegian Cancer Society and the Research Council of Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Differentiating post-radiation MRI changes from progressive disease (PD) in glioblastoma (GBM) patients represents a major challenge. The clinical problem is two-sided; avoid termination of effective therapy in case of pseudoprogression (PsP) and continuation of ineffective therapy in case of PD. We retrospectively assessed the incidence, management, and prognostic impact of PsP and analyzed factors associated with PsP in a GBM patient cohort.

Methods

Consecutive GBM patients diagnosed in the South-Eastern Norway Health Region from 2015 to 2018 who had received RT and follow-up MRI were included. Tumor, patient, and treatment characteristics were analyzed in relationship to re-evaluated MRI examinations at 3 and 6 months post-radiation using Response Assessment in Neuro-Oncology criteria.

Results

A total of 284 patients were included in the study. PsP incidence 3 and 6 months post-radiation was 19.4% and 7.0%, respectively. In adjusted analyses, methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter and the absence of neurological deterioration were associated with PsP at both 3 (p < .001 and p = .029, respectively) and 6 months (p = .045 and p = .034, respectively) post-radiation. For patients retrospectively assessed as PD 3 months post-radiation, there was no survival benefit of treatment change (p = .838).

Conclusions

PsP incidence was similar to previous reports. In addition to the previously described correlation of methylated MGMT promoter with PsP, we also found that absence of neurological deterioration significantly correlated with PsP. Continuation of temozolomide courses did not seem to compromise survival for patients with PD at 3 months post-radiation; therefore, we recommend continuing adjuvant temozolomide courses in case of inconclusive MRI findings.

Schlagwörter

Stichwörter der Autor:innen

associated factorschemoradiotherapyglioblastomaprognostic factors pseudoprogression

Autor:innen und Institutionen

  • Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.
  • Vilhelm Magnus Laboratory, Institute for Surgical Research, Oslo University Hospital, Oslo, Norway.
  • Cancer Registry of Norway, Oslo, Norway.
  • Department of Pathology, Oslo University Hospital, Oslo.

ORCID-Profile: Hanne Blakstad, Henning Leske, Eirik Helseth, Petter Brandal

Förderung

  • European Union’s Horizon 2020 Programmes
  • European Research Council
  • Norwegian Cancer Society and the Research Council of Norway
  • South-Eastern Norway Regional Health Authority

Zitieren

APA

Blakstad, H., Mendoza Mireles, E. E., Heggebø, L. C., Magelssen, H., Sprauten, M., Johannesen, T. B., Vik-Mo, E. O., Leske, H., Niehusmann, P., Skogen, K., Helseth, E., Emblem, K. E., & Brandal, P. (2024). Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study. Neuro-Oncology Practice, 11(1), 36-45. https://doi.org/10.1093/nop/npad063

Vancouver

Blakstad H, Mendoza Mireles EE, Heggebø LC, Magelssen H, Sprauten M, Johannesen TB, et al. Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study. Neuro-Oncology Practice. 2024;11(1):36-45. doi:10.1093/nop/npad063

BibTeX
@article{Blakstad2024,
  author = {Blakstad, Hanne and Mendoza Mireles, Eduardo Erasmo and Heggebø, Liv Cathrine and Magelssen, Henriette and Sprauten, Mette and Johannesen, Tom Børge and Vik-Mo, Einar Osland and Leske, Henning and Niehusmann, Pitt and Skogen, Karoline and Helseth, Eirik and Emblem, Kyrre Eeg and Brandal, Petter},
  title = {Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study},
  journal = {Neuro-Oncology Practice},
  year = {2024},
  volume = {11},
  number = {1},
  pages = {36--45},
  doi = {10.1093/nop/npad063}
}
Kostenlos starten →